ALIM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALIM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Alimera Sciences's interest expense for the three months ended in Jun. 2024 was $ -3.15 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-13.72 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Alimera Sciences's Operating Income for the three months ended in Jun. 2024 was $ -0.08 Mil. Alimera Sciences's Interest Expense for the three months ended in Jun. 2024 was $ -3.15 Mil. Alimera Sciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Alimera Sciences's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -4.87 | -5.38 | -5.41 | -5.88 | -10.19 |
Alimera Sciences Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Interest Expense | Get a 7-Day Free Trial | -1.69 | -2.07 | -4.75 | -3.74 | -3.15 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences (NAS:ALIM) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Alimera Sciences's Interest Expense for the three months ended in Jun. 2024 was $-3.15 Mil. Its Operating Income for the three months ended in Jun. 2024 was $-0.08 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2024 was $69.73 Mil.
Alimera Sciences's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as
Alimera Sciences did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Margaret Pax | director | 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005 |
John Snisarenko | director | C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Pizzo Peter J. Iii | director | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Erin Parsons | director | 97 WILLISTON RD, BROOKLINE MA 02445 |
Caligan Partners Lp | 10 percent owner | 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
Ross D Demont | director | 51 PICKWICK ROAD, NEWTON MA 02465 |
C. Daniel Myers | other: Chairman Emeritus | 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
David Edward Johnson | 10 percent owner | 590 MADISON AVENUE, NEW YORK NY 10022 |
Velan Capital Master Fund Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Management Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Holdings Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Adam Morgan | director | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Investment Management Lp | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Velan Capital Spv I Llc | 10 percent owner | 1055B POWERS PLACE, ALPHARETTA GA 30009 |
Balaji Venkataraman | 10 percent owner | FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
From GuruFocus
By GuruFocus Research • 08-03-2023
By sperokesalga sperokesalga • 03-24-2023
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 05-17-2023
By sperokesalga sperokesalga • 02-27-2023
By GuruFocus Research • 10-26-2023
By sperokesalga sperokesalga • 02-22-2023
By GuruFocus Research • 09-16-2023
By GuruFocus Research • 08-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.